Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;35(8):665.
doi: 10.1358/dof.2010.035.08.1513490.

Anti-GD2 Strategy in the Treatment of Neuroblastoma

Richard K Yang, Paul M Sondel

Anti-GD2 Strategy in the Treatment of Neuroblastoma

Richard K Yang et al. Drugs Future. 2010.

Abstract

The prognosis for advanced neuroblastoma remains poor with high risk of recurrence after consolidation. Therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Monoclonal Antibodies and Immunocytokines. (a) A chimeric monoclonal antibody (mAb) combines the constant region of a human antibody with the variable domain of a murine antibody. The antigen specificity is conferred by the murine variable domain. (b) In the humanised mAb, the murine framework determinants of both the heavy and light chains are replaced with human framework determinants, but the antigen specificity of the original murine mAb is retained. (c,d) Fusion proteins or immunocytokines combine the mAb with covalently linked cytokines, such as molecules of interleukin 2 (IL-2), to the end of each of the heavy chains at the C-terminus.
See this image and copyright information in PMC

References

    1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008 Feb;55(1):97–120. x. Review. [PMID: 18242317] - PubMed
    1. Ishola TA, Chung DH. Neuroblastoma. Surg Oncol. 2007 Nov;16(3):149–156. Epub 2007 Oct 31. Review. [PMID: 17976976] - PubMed
    1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric Oncology. Philadelphia: Lippincott; 2002. pp. 895–938.
    1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 Oct 14;341(16):1165–1173. [PMID: 10519894] - PubMed
    1. Brodeur GM. Significance of intratumoral genetic heterogeneity in neuroblastomas. Med Pediatr Oncol. 2002 Feb;38(2):112–113. [PMID: 11813176] - PubMed

LinkOut - more resources